References
Sudlow CLM, Counsell CE. Problems with the UK governments risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326: 388–92
Wright M. Getting bang for buck from patient access schemes. PJ Online 2009 Nov 4 [online]. Available from URL: (http://www.pjonline.com/news/getting_bang_for_buck_from_patient_access_schemes) [Accessed 2009 Nov 30]
Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113–42
McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 2010; 28 (2): 143–52
Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010; 28 (2): 163–70
Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010; 28 (2): 153–62
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Menon, D., McCabe, C.J., Stafinski, T. et al. Principles of Design of Access with Evidence Development Approaches. Pharmacoeconomics 28, 109–111 (2010). https://doi.org/10.2165/11530860-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11530860-000000000-00000